GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Medpace Holdings Inc (NAS:MEDP) » Definitions » Change In Receivables
中文

Medpace Holdings (Medpace Holdings) Change In Receivables : $-25 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Medpace Holdings Change In Receivables?

Medpace Holdings's change in receivables for the quarter that ended in Mar. 2024 was $19 Mil. It means Medpace Holdings's Accounts Receivable declined by $19 Mil from Dec. 2023 to Mar. 2024 .

Medpace Holdings's change in receivables for the fiscal year that ended in Dec. 2023 was $-48 Mil. It means Medpace Holdings's Accounts Receivable increased by $48 Mil from Dec. 2022 to Dec. 2023 .

Medpace Holdings's Accounts Receivable for the quarter that ended in Mar. 2024 was $271 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Medpace Holdings's Days Sales Outstanding for the three months ended in Mar. 2024 was 48.33.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Medpace Holdings's liquidation value for the three months ended in Mar. 2024 was $-514 Mil.


Medpace Holdings Change In Receivables Historical Data

The historical data trend for Medpace Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medpace Holdings Change In Receivables Chart

Medpace Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.26 -5.53 -24.98 -66.92 -48.28

Medpace Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.34 -17.39 -17.58 -8.97 19.12

Medpace Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medpace Holdings  (NAS:MEDP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Medpace Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=270.685/511.044*91
=48.33

2. In Ben Graham's calculation of liquidation value, Medpace Holdings's accounts receivable are only considered to be worth 75% of book value:

Medpace Holdings's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=407.01-1124.247+0.75 * 270.685+0.5 * 0
=-514

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medpace Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of Medpace Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Medpace Holdings (Medpace Holdings) Business Description

Traded in Other Exchanges
Address
5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.
Executives
Susan E Burwig officer: Exec. VP, Operations C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
August J. Troendle director, 10 percent owner, officer: CEO 5375 MEDPACE WAY, CINCINNATI OH 45227
Medpace Investors, Llc 10 percent owner 4620 WESLEY AVENUE, CINCINNATI OH 45212
Robert O. Kraft director ONE CVS DRIVE, WOONSOCKET RI 02895
Kevin M. Brady officer: CFO & Treasurer MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Stephen P Ewald officer: General Counsel & Corp. Secy. C/O MEDPACE HOLDINGS,INC., 5375 MEDPACE WAY, CINTINNATI OH 45227
Femida H. Gwadry-sridhar director 5375 MEDPACE WAY, CINCINNATI OH 45227
Ashley M. Keating director 5375 MEDPACE WAY, CINCINNATI OH 45227
Davenport Fred B Jr director
Brian T Carley director C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Mccarthy Cornelius P. Iii director 5375 MEDPACE WAY, CINCINNATI OH 45227
Jesse J Geiger officer: CFO & COO, Lab Operations C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI OH 45227
Tom C King director 5375 MEDPACE WAY, CINCINNATI OH 45227
Medpace Limited Partnership 10 percent owner EAST WING, TRAFALGAR COURT, LES BANQUES, ST. PETER PORT, CHANNEL ISLANDS Y7 GY1 3PP
Cinven Capital Management (v) General Partner Ltd 10 percent owner EAST WING, TRAFALGAR COURT, LES BANQUES, ST. PETER PORT Y7 GY1 3PP

Medpace Holdings (Medpace Holdings) Headlines